Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
Type:
Grant
Filed:
March 15, 2016
Date of Patent:
April 25, 2017
Assignee:
Gruenenthal GmbH
Inventors:
Stefanie Frosch, Klaus Linz, Thomas Christoph
Abstract: Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
April 18, 2017
Assignee:
Gruenenthal GmbH
Inventors:
Robert Frank-Foltyn, Gregor Bahrenberg, Thomas Christoph, Klaus Schiene, Jean De Vry, Nils Damann, Sven Frormann, Bernhard Lesch, Jeewoo Lee, Yong-Soo Kim, Myeong-Seop Kim, Derek Saunders, Hannelore Stockhausen
Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Application
Filed:
October 7, 2016
Publication date:
April 13, 2017
Applicant:
GRÜNENTHAL GMBH
Inventors:
Stefan SCHUNK, Melanie Reich, René Michael Koenigs
Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Application
Filed:
October 7, 2016
Publication date:
April 13, 2017
Applicant:
GRÜNENTHAL GMBH
Inventors:
Stefan Schunk, Melanie Reich, René Michael Koenigs
Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
Type:
Application
Filed:
September 9, 2016
Publication date:
March 16, 2017
Applicant:
GRÜNENTHAL GMBH
Inventors:
KLAUS WENING, Sebastian Schwier, Ulrike Bertram
Abstract: The invention relates to a method for the preparation of a powdery pharmaceutical composition comprising a pharmaceutical excipient and a pharmaceutical component, the method comprising the step of extruding a mixture of the pharmaceutical excipient and the pharmaceutical component in an extruder at a temperature profile allowing a liquid melt of the mixture to congeal in the extruder and to exit the extruder in form of a powder.
Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
Type:
Application
Filed:
September 2, 2016
Publication date:
February 23, 2017
Applicant:
Grünenthal GmbH
Inventors:
Elisabeth Arkenau-Maric, Johannes Bartholomäus
Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
Type:
Grant
Filed:
June 17, 2016
Date of Patent:
February 7, 2017
Assignee:
GRÜNENTHAL GMBH
Inventors:
Melanie Reich, Stefan Schunk, Florian Jakob, Henning Steinhagen, Nils Damann, Michael Haurand, Marc Rogers, Kathy MacKenzie
Abstract: The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.
Type:
Application
Filed:
October 13, 2016
Publication date:
February 2, 2017
Applicant:
GRUENENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Grant
Filed:
July 15, 2015
Date of Patent:
January 17, 2017
Assignee:
GRUENENTHAL GMBH
Inventors:
Antonio Nardi, Florian Jakob, Ingo Konetzki, Tobias Craan, Christian Hesslinger
Abstract: The invention relates to novel substituted pyrimidine compounds of general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Grant
Filed:
July 15, 2015
Date of Patent:
January 10, 2017
Assignee:
GRUENENTHAL GMBH
Inventors:
Antonio Nardi, Florian Jakob, Ingo Konetzki, Tobias Craan, Christian Hesslinger
Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
Type:
Application
Filed:
September 14, 2016
Publication date:
January 5, 2017
Applicant:
GRÜNENTHAL GMBH
Inventors:
Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.
Type:
Application
Filed:
September 7, 2016
Publication date:
December 29, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Ingo FRIEDRICH, Richard FUHRHERR, Silke MÖSCHTER, Simone WENGNER
Abstract: The invention relates to a dosage that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
Type:
Application
Filed:
September 6, 2016
Publication date:
December 29, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS, HEINRICH KUGELMANN
Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
Type:
Grant
Filed:
October 15, 2015
Date of Patent:
December 27, 2016
Assignee:
GRÜNENTHAL GMBH
Inventors:
Ingo Konetzki, Florian Jakob, Tobias Craan, Christian Hesslinger, Paul Ratcliffe, Antonio Nardi
Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
Type:
Application
Filed:
September 6, 2016
Publication date:
December 22, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS
Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
Type:
Application
Filed:
August 29, 2016
Publication date:
December 22, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
Type:
Application
Filed:
September 2, 2016
Publication date:
December 22, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
JOHANNES BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.
Type:
Application
Filed:
September 2, 2016
Publication date:
December 22, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS
Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
Type:
Application
Filed:
August 31, 2016
Publication date:
December 22, 2016
Applicant:
GRÜNENTHAL GMBH
Inventors:
Elisabeth ARKENAU-MARIC, Johanness BARTHOLOMÄUS, Heinrich KUGELMANN